CAR-T Immunotherapy Research

As revolutionary immuno-oncology changes to cancer treatment, cell therapies have attracted widespread attention with their high clinical remission rate in hematological cancers. Since 2018, cell therapies have accounted for more remissions than cancer vaccines, with chimeric antigen receptor T (CAR-T) therapies leading the global cell therapy development race. With rapid development in the past ten years, CAR-T immunotherapy has become a hot area in which commercial organizations compete fiercely and universities ans industry collaborate intensively.¹

Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack and destroy chemotherapy-resistant cancer.² CAR-T cell therapy leverages the power of the patient's own immune system by serving as a bridge to connect genetically modified T cells to the surface antigens of tumor cells based on targeted ligands. Clinical trials have demonstrated compelling overall response and survival rates in individuals with B-cell malignancies.³

CAR-T Immunotherapy: The most popular CAR-T Targets

According to data from the U.S. Patent and Trademark Office (USPTO), the number of CAR-T related patents filed showed a sharp increase during the last decade. In this context, the USA and China are leading the way with the largest increase in patent documents, followed by the European countries. A look at the most common targets in CAR-T patent documents reveals an interesting and clearly structured picture. CD19 is by far the most worked target, followed by BCMA, CD20, Mesothelin, PD-1/PD-L1.

Below you will find our top products related to the most relevant research targets. Click on the respective link to see all product data, references, images and validation data.

CD19

BCMA

CD20

Mesothelin

PD-1/PD-L1

HER-2

CD22

EGFR

MUC1

HLA

EGFRvIII

CD33

CD123

CD30

ROR1

GPC3

CEA

PSMA

CD38

GD2

References

1. Lyu, Feng, Chen, Hu: "The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape." in: Nature biotechnology, Vol. 38, Issue 12, pp. 1387-1394, (2021) (PubMed).
2. Feins, Kong, Williams, Milone, Fraietta: "An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer." in: American journal of hematology, Vol. 94, Issue S1, pp. S3-S9, (2020) (PubMed).
3. Lamprecht, Dansereau: "CAR T-Cell Therapy: Update on the State of the Science." in: Clinical journal of oncology nursing, Vol. 23, Issue 2, pp. 6-12, (2020) (PubMed).